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Introduction: Increasing evidence indicates that microRNAs (miRNAs) are important players in oncogenesis.
Considering the widespread use of aromatase inhibitors (AIs) in endocrine therapy as a first-line treatment for
postmenopausal estrogen receptor α–positive breast cancer patients, identifying deregulated expression levels of
miRNAs in association with AI resistance is of utmost importance.
Methods: To gain further insight into the molecular mechanisms underlying the AI resistance, we performed
miRNA microarray experiments using a new model of acquired resistance to letrozole (Res-Let cells), obtained by
long-term exposure of aromatase-overexpressing MCF-7 cells (MCF-7aro cells) to letrozole, and a model of acquired
anastrozole resistance (Res-Ana cells). Three miRNAs (miR-125b, miR-205 and miR-424) similarly deregulated in both
AI-resistant cell lines were then investigated in terms of their functional role in AI resistance development and
breast cancer cell aggressiveness and their clinical relevance using a cohort of 65 primary breast tumor samples.
Results: We identified the deregulated expression of 33 miRNAs in Res-Let cells and of 18 miRNAs in Res-Ana cells
compared with the sensitive MCF-7aro cell line. The top-ranked Kyoto Encyclopedia of Genes and Genomes
pathways delineated by both miRNA signatures converged on the AKT/mTOR pathway, which was found to be
constitutively activated in both AI-resistant cell lines. We report for the first time, to our knowledge, that ectopic
overexpression of either miR-125b or miR-205, or the silencing of miR-424 expression, in the sensitive MCF-7aro cell
line was sufficient to confer resistance to letrozole and anastrozole, to target and activate the AKT/mTOR pathway
and to increase the formation capacity of stem-like and tumor-initiating cells possessing self-renewing properties.
Increasing miR-125b expression levels was also sufficient to confer estrogen-independent growth properties to the
sensitive MCF-7aro cell line. We also found that elevated miR-125b expression levels were a novel marker for poor
prognosis in breast cancer and that targeting miR-125b in Res-Let cells overcame letrozole resistance.
Conclusion: This study highlights that acquisition of specific deregulated miRNAs is a newly discovered alternative
mechanism developed by AI-resistant breast cancer cells to achieve constitutive activation of the AKT/mTOR
pathway and to develop AI resistance. It also highlights that miR-125b is a new biomarker of poor prognosis and a
candidate therapeutic target in AI-resistant breast cancers.* Correspondence: pascale.cohen@univ-lyon1.fr
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In approximately 75% of postmenopausal patients, breast
cancer is a hormone-dependent disease that relies on
the mitogenic effects of estrogen to drive carcinogenesis.
Endocrine therapies, including estrogen receptor α
(ERα) modulators and aromatase inhibitors (AIs), are
the most suitable treatment for ERα-positive (ER+)
breast cancer patients. Recently, nonsteroidal AIs (for
example, letrozole, anastrozole) that block the biosyn-
thesis of estrogens have proven more effective than the
selective estrogen receptor modulator tamoxifen (Tam)
in the treatment of postmenopausal patients with ER+
breast cancer [1]. Despite the demonstrated clinical effi-
cacy of AIs, however, de novo and acquired resistance
still occurs and constitutes a major impediment to suc-
cessful therapy.
At present, acquired resistance to endocrine therapy is
considered to be a progressive, stepwise phenomenon
whereby breast cancer cells are converted from an
estrogen-dependent phenotype, which is responsive to
endocrine therapy, to a nonresponsive phenotype and
eventually to an estrogen-independent phenotype. Among
the molecular mechanisms involved in the acquisition of
endocrine resistance, a switch from steroid signaling to
growth factor signaling pathways has been the focus of re-
cent studies, which have demonstrated the activation of
the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian
target of rapamycin (mTOR) and/or mitogen-activated
protein kinase (MAPK) pathways, both in breast cancer
cell lines and in breast tumors [2-8]. Activation of these
survival pathways may contribute to endocrine resistance
via the activation of kinases in an ER-dependent [9] as well
as ER-independent fashion [2,10].
MicroRNAs (miRNAs) are short, noncoding RNAs that
generally base pair within the 3′ untranslated (3′UTR)
region of target mRNAs, causing translational inhibition
and/or mRNA degradation. A growing body of evidence
favors miRNAs’ being important players in oncogenesis
[11], with some able to act as oncogenes, others as tumor
suppressors and others displaying either oncogenic or
tumor-suppressive activities, depending on the tissue and
tumor context [11-13]. Widespread deregulated expres-
sion of miRNAs would thus be expected to represent an-
other hallmark of cancer, providing not only biomarkers
but also novel therapeutic targets. Recent investigations
have revealed that miRNAs are involved in the deve-
lopment of drug resistance, but little is known about
the miRNA-driven molecular mechanisms governing the
drug-resistant signal transduction network [14,15].
Increasing amounts of data support an involvement of
miRNAs in estrogen action and/or in endocrine resis-
tance, with most studies dedicated to Tam or fulvestrant
resistance. A close cross-talk appears to exist between
ERα and specific miRNAs, with several miRNAs foundto regulate ERα, which conversely negatively regulates
the expression of some miRNAs [16]. Complexity was
further revealed by the observation that miRNAs are
also able to regulate ERα activity by repressing the ex-
pression of ERα transcriptional cofactors [16]. Further-
more, some miRNA signatures have been identified by
microarray analysis in Tam- or fulvestrant-resistant
breast cancer cell lines [17,18]. Several miRNAs, such as
the miR-200 family [19], miR-375 [20], miR-221/222
[21,22], miR-15a/16 [23], miR-101 and miR-519a [24,25],
have been shown to regulate molecular targets or func-
tional signaling pathways associated with Tam or fulves-
trant resistance. To date, only one study research team
has investigated miRNA expression profiles associated
with AI resistance [26]. They found that miR-128a, pre-
viously identified as being associated with breast cancer
aggressiveness [27], was highly expressed in letrozole-
resistant breast cancer cells compared with their sensi-
tive counterpart and targeted the transforming growth
factor β (TGF-β) signaling pathway.
Bearing in mind that any one given miRNA can have
several targets, some belonging to the same functional
network or signaling pathway, and that the 3′UTR of a
single gene is frequently targeted by several different
miRNAs, our primary aim in this study was to capture a
global view of the miRNA expression profiles associated
with AI resistance in the hope of identifying common
miRNA-targeted specific functional networks. Our sec-
ond aim was to select the most relevant miRNAs that
represent candidate biomarkers or putative therapeutic
targets of ER+ breast cancers treated by AIs. In this study,
we performed a large-scale investigation of miRNA ex-
pression profiles associated with letrozole or anastrozole
resistance using two in vitro models of AI-acquired resis-
tance. We report the acquisition of several deregulated
miRNAs as a newly discovered alternative mechanism de-
veloped by the AI-resistant breast cancer cells to achieve
constitutive activation of the AKT/mTOR pathway and to
develop AI resistance. We also demonstrate, for the first
time to our knowledge, that elevated miR-125b expression
levels constitute a novel marker for poor prognosis in
breast cancer and that targeting miR-125b in letrozole-
resistant cells overcame letrozole resistance.
Methods
Establishment of resistant cell lines and culture conditions
A new letrozole-resistant cell line, denoted Res-Let, was
established from the ER+ MCF-7-derived breast cancer
cell line stably transfected with the human aromatase
gene (MCF-7aro cells, kindly provided by Dr Shiuan
Chen) [28]. The MCF-7aro cells were exposed during a
20-week period to increasing concentrations (1, 3 and
5 μM) of letrozole (Novartis, Basel, Switzerland) in
Dulbecco’s modified Eagle’s medium without phenol red,
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charcoal-treated fetal calf serum (DCC medium) con-
taining 25 nM of 4-androstenedione (AD) (Sigma-
Aldrich, St Louis, MO, USA). The previously described
Res-Ana cells [6] were used as a model of acquired re-
sistance to anastrozole. The cells were purged in DCC
medium for 4 days prior to each experiment described
below, then treated with 25 nM AD combined, or not,
with the appropriate treatment. Media and treatments
were changed every 2 days.
Cytotoxicity assay
A total of 104 cells/well were plated in a 96-well plate and
treated for 4 days with 25 nM of AD combined with letro-
zole, anastrozole (AstraZeneca, London, UK) or MK-2206
(Merck Sharp & Dohme, Whitehouse Station, NJ, USA).
Cell viability was assessed as previously described [29].
Total RNA extraction
Total RNA was prepared from cell lines or tumor samples
using the miRNeasy Mini Kit (Qiagen, Hilden, Germany).
RNA integrity was checked using the BioAnalyzer 2100
(Agilent Technologies, Palo Alto, CA, USA).
GeneChip miRNA 3.0 Array Affymetrix experiment and
analysis
For MCF-7aro, Res-Let or Res-Ana cells, two inde-
pendent cell culture replicates were used to generate
total RNA. Complex probes were produced from total
RNA using the FlashTag™ Biotin HSR RNA labeling kit
(Affymetrix, Santa Clara, CA, USA) and then hybridized
to each GeneChip miRNA 3.0 array according to the
manufacturer’s recommendations (Affymetrix). Expe-
riments were performed by the ProfileXpert platform
(Lyon, France). Scanned images of microarray chips were
analyzed using Expression Console software (Affymetrix)
with the default settings. Raw data were processed using
different algorithms. In particular, the detection above
background algorithm and the robust multiarray average
background adjustment algorithm were performed to re-
move the background value. For each cell culture repli-
cate, expression values were given as fold changes (FCs)
corresponding to the ratio of the value for resistant cells
to that for MCF-7aro cells. Only probe sets with FC values
superior to the selected cutoff (greater than or equal to
1.7 or less than or equal to −1.7) in the two independent
cell culture replicates were considered to be differentially
expressed. The microarray data have been deposited in
the Gene Expression Omnibus (GEO) database [GEO:
GSE43766].
Bioinformatic analysis
Expression profiles of the deregulated miRNAs were
visualized using the Cluster and TreeView softwareprograms [30]. The list of deregulated miRNAs was then
submitted to the DIANA-mirPath algorithm, using the
TargetScan 5 search algorithm, to find specific pathways
that may be altered by miRNA modulations [31]. The
miRWalk database was used to identify the miRNAs tar-
geting the AKT pathway [32].
Real-time quantitative PCR
Reverse transcription was carried out using the Universal
cDNA Synthesis Kit II (Exiqon, Vedbæk, Denmark).
Quantitative real-time PCR (RTQ-PCR) measurements
were performed using the ExiLENT SYBR Green Master
Mix with commercially available primers for miRNAs
(miR-125b-5p, miR-205-5p and miR-424-3p) as recom-
mended by the manufacturer (Exiqon). U6 small nuclear
RNA was used as an endogenous control for nor-
malization [33].
Transfection of miRNA oligonucleotides
MCF-7aro cells were transfected with 5 nM of miR-
125b-5p, miR-205-5p or miR-424-3p mirVana miRNA
mimics (Life Technologies, Carlsbad, CA, USA) or with
5 nM of miR-424-3p, miR-125b-5p or miR-205-5p in-
hibitors (Exiqon) or corresponding negative controls
using Lipofectamine RNAiMAX transfection reagent
(Life Technologies). RNA extraction, RTQ-PCR expe-
riments, Western blot analysis and cytotoxicity assays
using cells transfected with miRNA mimics or inhibitors
were performed 72 hours posttransfection.
Mammosphere assay
After transfection, or not, with miRNA oligonucleotides,
single-cell suspensions were seeded using nonadherent
mammosphere culture conditions [34]. After 7 days,
primary mammospheres (PMs) were counted, collected,
trypsinized, transfected again with miRNA oligonucleo-
tides and replated for 10 days in nonadherent culture con-
ditions to generate second-generation mammospheres.
The culture media were replenished every 2 to 3 days.
Proliferation analysis in estrogen-free conditions
A total of 3 × 104 cells/well were plated in a 24-well plate
and grown for 2, 3.5 or 6 days in steroid-free medium
before counting.
Western blot analysis
Western blot experiments were performed as previously
described [35]. The antibodies used were anti-phospho-
Ser473-AKT (clone 587 F11, 1:1,000 dilution), anti-AKT
(clone C67E7, 1:1,000 dilution), anti-phospho-Ser9-GSK-
3β (catalog number 9331, 1:1,000 dilution), anti-GSK3β
(clone 27C10, 1:1,000 dilution), anti-phospho-thr389-
p70S6K (clone E10, 1:1,000 dilution), anti-p70S6K (clone
49D7, 1:1,000 dilution) (all from Cell Signaling Technology,
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1:5,000; Sigma-Aldrich).
Breast tumor cohorts
Women with primary breast tumors and known clinical
follow-up who had not received any therapy before sur-
gery and who relapsed, or not, while receiving endocrine
therapy and/or chemotherapy were recruited from the
BB-0033-00050 Centre de Ressources Biologiques of the
Centre Léon Bérard (Lyon, France) (Additional file 1:
Table S1). Informed consent was obtained from all pa-
tients, and the study was approved by the center’s ethics
committee. It was checked that the average relapse-free
survival (RFS) and overall survival of the cohort used in
this study were similar to those of a larger breast cancer
cohort (N = 2,978) [36,37]. Our cohort was subdivided
into breast cancer subtypes according to the St Gallen
recommendation [38] using the immunohistological
markers ER, progesterone receptor (PR), human epider-
mal growth factor receptor 2 (HER2)/neu/ERBB2 (recep-
tor tyrosine kinase) and the Scarff-Bloom-RichardsonFigure 1 Pharmacological response of resistant cell lines to aromatas
to anastrozole (A) or letrozole (B) and of MCF-7aro and Res-Let cells to letr
(mean ± SD from three independent experiments). *P < 0.05, **P < 0.01 and(SBR) grade (indicative of proliferation) as follows: HR+
(ER+ and/or PR+), luminal A (ER+ and/or PR+, HER2−,
low proliferation (SBR1 or SBR2)) or luminal B (ER+
and/or PR+, HER2+ and/or SBR3 (high proliferation)).
IBM SPSS software (IBM, Armonk, NY, USA) was used
for all statistical analyses in which the prognostic value
of each miRNA was analyzed. The data are divided, at
the value representing the median level of expression of
a particular miRNA, into two groups with either high or
low expression.
Other experimental materials and procedures are de-
scribed in Additional file 2.
Results
Establishment and characterization of a new in vitro
model of acquired resistance to letrozole
Our group has previously described a model of acquired
resistance to anastrozole (Res-Ana cells) [6] established
by long-term exposure of MCF-7aro [28]. The resulting
Res-Ana cells displayed significant resistance (in cytotox-
icity assays) to anastrozole (Figure 1A), but they alsoe inhibitors. Pharmacological response of MCF-7aro and Res-Ana cells
ozole (C) or anastrozole (D), as assessed by cytotoxicity assays
***P < 0.001 versus the corresponding MCF-7aro (Student’s t-test).
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work we established (see the Methods section) and char-
acterized a new cellular model of acquired resistance to
letrozole, the Res-Let cells. The Res-Let cells displayed
complete resistance to letrozole (Figure 1C) and, despite
being selected under letrozole exposure only, also sig-
nificantly decreased sensitivity to anastrozole, suggest-
ing, at least in part, common mechanisms of resistance
(Figure 1D).
As both ER-independent [2,10] and ER-dependent
[39-41] mechanisms have been described in long-term
AI resistance models, we investigated whether the AI re-
sistance acquired by the Res-Let cells was due to any
changes in aromatase function, ERα expression or ERα
activity. We found no differences in aromatase activity
and similar total inhibition between Res-Let and MCF-
7aro cells in the presence of letrozole or anastrozole
(Additional file 3: Figure S1A). Expression levels of ERα
protein remained unchanged between the two cell lines,
and we detected no phosphorylation at serine 118 or
serine 167 in either cell line (Additional file 3: Figure S1B).
Investigation of ERα transcriptional activity by estrogen
response element-luciferase assay revealed that both the
MCF-7aro and Res-Let cells displayed similar and low
basal ERα activity levels (Additional file 3: Figure S1C),
thus ruling out any ligand-independent activation of ERα
(consistent with the absence of any phosphorylation at
serines 118 and 167). 17β-estradiol (E2) treatment led to
similar increased ERα activity and treatment with the se-
lective estrogen receptor downregulator fulvestrant, which
induces inhibition and degradation of ERα, abolished the
E2-induced ERα activity (Additional file 3: Figure S1C).
Altogether, and similarly to the Res-Ana cells [6], these
data allowed us to rule out the acquired resistance of Res-
Let cells being ascribed to an altered ERα expression or
functionality, to an impaired activity of the aromatase, or
to any loss of inhibitory effects of AIs on the aromatase.
Identification of new deregulated miRNA signatures
associated with acquired aromatase inhibitor resistance in
Res-Let and Res-Ana cells
With the aim of selecting relevant deregulated miRNAs
associated with acquired letrozole or anastrozole resis-
tance, we analyzed miRNA expression profiles between
MCF-7aro and AI-resistant cells from two independent
cell culture replicates. The analysis led to the identifica-
tion of miRNAs associated with AI resistance: 33 miR-
NAs reproducibly deregulated between the Res-Let and
the MCF-7aro cells (15 upregulated and 18 down-
regulated), 18 miRNAs reproducibly deregulated (8 up-
regulated and 10 downregulated) between the Res-Ana
and the MCF-7aro cells, of which 6 miRNAs similarly
deregulated in both AI-resistant cell lines (Figure 2).
Details of the corresponding FC values are presented inTable 1. Interestingly, 16 (approximately 36%) of these
45 miRNAs have previously been ascribed to “estrogen
action” (that is, suppressed or stimulated under E2 or
ERα ligands, regulated by ERα, regulating ERα, dere-
gulated in breast cancer or deregulated in endocrine re-
sistance) [16,42] (Figure 2, miRNAs with a red asterisk).
In the only study in which miRNA expression profiles
associated with AI resistance were investigated, upregula-
tion of miR-128a (miR-128-1) was identified in letrozole-
resistant cells [26]. Our data confirmed this (Figure 2 and
Table 1), thus reinforcing the relevance of our AI
resistance-associated miRNA signature. The finding of six
miRNA array probe sets (miR-125b, miR-205, miR-30a,
miR-424, miR-1292 and miR-4492) (Figure 3A) reprodu-
cibly and commonly deregulated in both the letrozole- and
anastrozole-resistant cells suggests the existence of com-
mon molecular mechanisms associated with AI resistance.
We selected for RTQ-PCR validation three candidate miR-
NAs (miR-125b-5p, miR-205-5p and miR-424-3p (corre-
sponding respectively to the miR-125b, miR-205 and miR-
424 array probe sets)), based on the following criteria: high
expression values (Figure 3A) and belonging to the most
deregulated miRNAs (Table 1). Validation by RTQ-PCR of
the increased expression levels of miR-125b and miR-205
and decreased expression levels of miR-424 in both Res-
Let cells and Res-Ana cells compared with MCF-7aro cells
(Figure 3B) showed good consistency with the FC deter-
mined by microarray analysis (Table 1).
Deregulated expression of miR-125b, miR-205 and miR-424
confers de novo aromatase inhibitor resistance in MCF-7aro
cells and aggressive features of endocrine resistance
We compared sensitive MCF-7aro cells transfected with
either the mimic of miR-125b, the mimic of miR-205 or
the inhibitor for miR-424 (Figures 3C and 3D) to their
respective transfected negative controls, searching for
any signs of acquisition of a phenotype similar to that
developed by the AI-resistant cells. The MCF-7aro cells
transfected with either miR-125b or miR-205 mimics be-
came significantly resistant to letrozole (both at 10−6 M
and 10−5 M), with a significantly greater impact of miR-
125b (Figure 3E) that very closely resembled the resist-
ance displayed by the Res-Let cells (Figure 1C). MiR-424
expression silencing under 10−5 M, but not 10−6 M,
treatment conditions in MCF-7aro cells significantly de-
creased letrozole sensitivity (Figure 3F). As demonstrated
in Figures 3G and 3H, ectopic overexpression of miR-
125b or miR-205, or miR-424 silencing, all conferred to
MCF-7aro cells complete resistance to both 10−6 M and
10−5 M anastrozole treatment, comparable to that dis-
played by the Res-Ana cells (Figure 1A). Altogether, these
data demonstrate the successful de novo resistance to both
letrozole and anastrozole achieved by mimicking in MCF-
7aro cells the miR-125b, miR-205 or miR-424 expression
Figure 2 Deregulated microRNA expression profiles associated with aromatase inhibitor resistance. Dendogram of 45 micro RNA (miRNA)
probe sets deregulated at the basal level in the Res-Let and Res-Ana cells as compared with the MCF-7aro cells in two independent cell cultures
(replicates 1 and 2). Using the Cluster and TreeView software packages, the miRNAs were ordered according to their degree of similarity after
hierarchical clustering of their expression profiles. Each column represents a cell line replicate, and each row represents a miRNA. Expression levels
above the median are presented in red, and those below are shown in green. Red asterisks represent miRNAs previously described as associated
with estrogen receptor (ER)/estrogen signaling, ER activity, breast cancer or endocrine resistance [16,42].
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Table 1 Deregulated microRNA expression associated with resistance to aromatase inhibitors
miRNA probe setsa Fold changeb
Res-Let Res-Ana
Replicate 1 Replicate 2 Replicate 1 Replicate 2
miR-125b 1.87 2.44 1.86 2.13
miR-205 2.76 2.86 2.19 2.99
miR-30a 1.71 3.17 2.97 2.15
miR-424 −2.33 −2.07 −1.76 −1.74
miR-1292 −3.02 −1.73 −2.06 −2.06
miR-4492 −2.51 −1.77 −2.14 −2.02
miR-21 1.73 1.70 NC NC
miR-125b-2 1.70 1.79 1.94 NC
miR-128-1/miR-128-2 1.70 1.70 NC NC
miR-146b 1.96 1.97 1.78 NC
miR-301a 1.80 2.63 NC NC
miR-494 3.14 1.70 NC NC
miR-501 2.28 2.46 NC NC
miR-1226 2.28 1.98 NC NC
miR-1247 2.09 3.85 2.20 NC
miR-3135b 1.98 1.81 NC NC
miR-3613 2.68 1.93 2.76 NC
miR-4667 1.91 2.30 1.91 NC
miR-23a −1.75 −2.24 NC NC
miR-23b −2.08 −1.98 −1.72 NC
miR-92a-1 −1.73 −2.55 NC −1.86
miR-193a −2.03 −1.82 NC NC
miR-193b −2.04 −2.07 NC NC
miR-324 −1.88 −1.85 NC NC
miR-330 −1.72 −1.72 NC NC
miR-4449 −1.76 −1.94 NC NC
miR-491 −2.63 −2.41 NC NC
miR-550a-1/miR-550a-2 −2.05 −1.78 NC −3.07
miR-671 −1.73 −1.85 −1.81 NC
miR-744 −1.78 −1.87 NC NC
miR-1180 −2.14 −1.78 NC NC
miR-1287 −1.80 −1.88 NC NC
miR-1296 −1.83 −2.83 NC −2.90
miR-31 NC 3.68 1.88 4.39
miR-100 NC 2.43 2.40 2.31
miR-504 NC NC 2.70 2.61
miR-1269 NC NC 2.41 2.10
miR-3065 NC NC 1.86 2.05
miR-29b-1 NC NC −2.11 −2.22
miR-342 −1.77 NC −1.74 −1.77
miR-422a NC NC −2.21 −1.84
miR-486 −2.46 NC −1.88 −1.80
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Table 1 Deregulated microRNA expression associated with resistance to aromatase inhibitors (Continued)
miR-4458 NC NC −2.73 −1.75
miR-4534 NC NC −2.42 −3.51
miR-4745 NC −1.80 −2.74 −3.74
aMicroRNAs (miRNAs) identified by the miRWalk database as being associated with a deregulated AKT pathway are shown in boldface type. bFold change (FC),
corresponding to the ratio of the value for Res-Let or Res-Ana cells to that for MCF-7aro cells. Only probe sets with FC values superior to the cutoff selected
(≥1.70 or less than or equal to −1.70) in the two independent cell culture replicates were considered to be differentially expressed. No change (NC) was defined
as values −1.70 < FC <1.70.
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regulated expression of miR-125b, miR-205 or miR-424 in
ER+ breast cancer cells thus represents, at least in part,
new molecular mechanisms involved in endocrine resis-
tance to different AI drugs.
A growing body of evidence supports the presence
within the tumor of heterogeneous subpopulations of
cells, including cancer stem cells or tumor-initiating cells
(TICs) with self-renewing properties generally associated
with an aggressive phenotype, escape from chemothe-
rapy or endocrine therapy, and the promotion of metas-
tases [6,43,44]. Indeed, residual breast cancer cells after
letrozole therapy have been shown to display TIC fea-
tures [44], and, compared with MCF-7aro cells, a higher
percentage of TICs with self-renewing properties have
been detected in letrozole- or anastrozole-resistant cells
[6,45]. We investigated self-renewal cell capacity by as-
sessing the efficiency of these cells in generating nonad-
herent mammospheres (mammosphere-forming efficiency
(MFE)). As shown in Figure 4A, nonadherent mammo-
sphere formation was significantly enriched starting from
Res-Let or Res-Ana cell populations compared with that
from the MCF-7aro cell population. Strikingly, transfec-
tion of MCF-7aro cells with the miR-125b or miR-205
mimics or with the miR-424 inhibitor increased MFE as
compared with their respective negative control (Figure 4A).
We then tested the self-renewal capability of the
mammosphere-forming cells by the PMs dissociated
into single cells and performed second-generation mam-
mosphere assays. The proportion of mammosphere-
forming cells isolated from the PMs greatly increased
through the second passage, thus indicating their ability to
self-renew. MiR-125b mimic transfection had the greatest
MFE-increasing impact (Figure 4B).
Several studies have now established that endocrine
resistance in ER+ breast cancer cells often involves a
switch from steroid signaling and endocrine therapy re-
sponsiveness to an estrogen-independent phenotype, and
in particular estrogen-independent growth properties
[46]. Consistently with these observations, both the
Res-Let and Res-Ana cells displayed a significantly grea-
ter magnitude of proliferation compared with MCF-7aro
control cells in estrogen-deprived conditions (Figure 4C),
highlighting their acquired increased capacity to pro-
liferate in the absence of any ERα agonist. Strikingly,ectopic overexpression of miR-125b in MCF-7aro cells
induced estrogen-independent growth in steroid-free
conditions (Figure 4D). Conversely, ectopic overexpres-
sion of miR-205 or miR-424 expression silencing had no
impact (Figures 4D and 4E).
Altogether, these data show that mimicking the deregu-
lated expression of three candidate miRNAs observed in
two cellular models of acquired AI resistance imposes on
the sensitive MCF-7aro cells: (1) a de novo pharma-
cological resistance to both anastrozole and letrozole, (2) a
selection of stem-like and tumor-initiating cells possessing
cell renewing properties and (3) for miR-125b only,
estrogen-independent growth properties.
Deregulated expression levels of miR-125b, miR-205 or
miR-424 are sufficient to activate the PI3K/AKT/mTOR
pathway
Target prediction analysis (DIANA-mirPath analysis) of
the miRNAs found to be deregulated in the Res-Let cells
allowed the identification of several significantly de-
regulated Kyoto Encyclopedia of Genes and Genomes
(KEGG) signaling pathways (Table 2) (P-values from 10−9
to 10−3). Interestingly, 7 of the 13 top-ranked signaling
pathways identified converged on the AKT pathway
(phosphatidylinositol signaling system, mTOR signaling
pathway, focal adhesion, insulin signaling pathway, ErbB
signaling pathway, MAPK signaling pathway, tight junc-
tion). Similarly, when we focused on the Res-Ana miRNA
signature, we found that 5 of the 11 top-ranked KEGG
signaling pathways identified after DIANA-mirPath ana-
lysis also converged on the AKT pathway and were identi-
fied by the Res-Let miRNA signature (Table 2) (P-values
from 10−10 to 10−4).
A query using the miRWalk database revealed that 16
miRNAs (approximately 36%) are described as targeting
the AKT pathway (miRNAs in boldface type in Table 1).
Of the six miRNAs commonly deregulated in Res-Let
and Res-Ana cells, only four could be analyzed by
DIANA-mirPath (miR-125b, miR-205, miR-424 and
miR-30a), which revealed that all four were sufficient to
identify the AKT pathway. In addition, the information
captured by both the DIANA-mirPath and miRWalk
database analyses revealed that 29% (98 of 338) of the
genes belonging to the AKT pathway are candidate tar-
gets for these four miRNAs (Figure 5A).
Figure 3 (See legend on next page.)
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Figure 3 MicroRNA-125b, microRNA-205 and microRNA-424 deregulations confer letrozole and anastrozole resistance. (A) Microarray
mean intensity values of the six microRNA (miR) probe sets commonly deregulated between Res-Let and Res-Ana cells. (B) Quantitative real-time PCR
(RTQ-PCR) validation of miR-125b-5p-, miR-205-5p- and miR-424-3p-deregulated expression levels in Res-Let and Res-Ana cells versus MCF-7aro cells
(mean ± SD from at least three independent experiments). (C) RTQ-PCR transfection efficiency validation in the MCF-7aro cells transfected with either
the negative control of mimics, miR-125b-5p mimic, miR-205-5p mimic or (D) with either the negative control of inhibitor or miR-424-3p inhibitor
(mean ± SD from at least three independent experiments). (E) Cell viability in response to letrozole in MCF-7aro cells transiently transfected with either
the negative control of mimics, miR-125b-5p mimic, miR-205-5p mimic or (F) with the negative control of inhibitor or miR-424-3p inhibitor. (G) Cell
viability in response to anastrozole in MCF-7aro cells transiently transfected with either the negative control of mimics, miR-125b-5p mimic, miR-205-5p
mimic or (H) with either the negative control of inhibitor or miR-424-3p inhibitor. (E), (F), (G) and (H) are representative of at least three independent
experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 (Student’s t-test).
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displayed a constitutive activation of the AKT/mTOR
pathway, as revealed by the activation of AKT (increase
in the phospho-AKT/total AKT ratio), coupled with an
increase in the phosphorylation level of the AKT down-
stream target GSK3β and an increase in the phosphoryl-
ation level of the mTOR downstream target p70S6K
(Figure 5B). Such constitutive activation of the AKT/
mTOR pathway is also present in the Res-Ana cells as
compared with the MCF-7aro cells and has previously
been described by our group [6]. Strikingly, transfecting
MCF-7aro cells with either the mimic of miR-125b, the
mimic of miR-205 or the inhibitor for miR-424 was suf-
ficient to confer activation of the AKT/mTOR pathway
(Figure 5C). Conversely, transfecting Res-Let cells with
either the inhibitor of miR-125b, the inhibitor of miR-
205 or the mimic of miR-424 led to a markedly
decreased activation of the AKT/mTOR pathway
(Figure 5D and Additional file 4: Figure S2). The AKT/
mTOR survival pathway plays a pivotal role in endocrine
resistance, and its activation is sufficient to confer
de novo resistance to anastrozole [6] or to letrozole
(Additional file 5: Figure S3 and [47]). Altogether, these
findings provide new evidence favoring the development
by AI-resistant cells of such a mechanism of deregulated
expression of specific miRNAs that leads to the constitu-
tive activation of the AKT/mTOR pathway.
MiR-125b expression levels are associated with poor
prognosis and with relapse in ER+ breast cancer patients
treated with endocrine therapy
To investigate the clinical relevance of miR-125b,
miR-205 and miR-424, we used RTQ-PCR to explore the
expression levels of these three miRNAs in a cohort of
65 primary breast tumor samples (Additional file 1:
Table S1). Strikingly, high expression levels of miR-125b,
though not miR-205 or miR-424, were associated with
shorter RFS (P = 0.009 by log-rank test) (Table 3 and
Figure 6A). The prognostic value of miR-125b expres-
sion levels was more informative than the SBR grade
(log-rank test) (Table 3), and the results of Fisher’s exact
test analysis revealed that miR-125b expression levels
were not associated with SBR grade (Additional file 6:Table S2). The prognostic value of miR-125b expression
levels was also more informative than the ER, PR or
HER2 conventional biomarkers in this cohort (log-rank
test) (Table 3). Lymph node status was associated with
shorter RFS (P = 0.006 by log-rank test) (Table 3). Prog-
nostic factors for RFS with a 0.05 significance level in
univariate analysis were then tested into a multivariate
Cox model using a backward selection procedure. Both
miR-125b levels and lymph node status persisted in the
model (P < 0.05), revealing that these biomarkers are in-
dependent prognostic markers (Table 3).
We then constructed a signature based on miR-125b
expression levels and lymph node status by dividing pa-
tients into three groups: patients expressing low levels
of miR-125b and having no or three or fewer involved
lymph nodes (group A), patients expressing high levels
of miR-125b and no or three or fewer involved lymph
nodes or those having more than three involved lymph
nodes and low expression of miR-125b (group B) and
patients expressing high levels of miR-125b and more
than three involved lymph nodes (group C). The re-
sulting Kaplan-Meier curves for RFS, shown in Figure 6B
(P = 0.001), indicated the stratification of the cohort into
a “good prognosis group” (group A), an “intermediate
prognosis group” (group B) and a “poor prognosis
group” (group C). Finally, we tested the miR-125b ex-
pression levels and lymph node status signature with
respect to RFS and found that the model associating miR-
125b expression levels and lymph node status was a better
fit (likelihood = 51.26) than either that with miR-125b
expression levels only (likelihood = 59.05, P = 0.005) or
that with lymph node status only (likelihood = 58.51,
P = 0.007). This demonstrated that, in this cohort, the
miR-125b expression level and lymph node status signa-
ture has the best prognostic value.
We then performed univariate analysis of the prognostic
value of miR-125b expression levels with regard to RFS in
the HR+/HER2− breast cancer subclass, and found that
high expression levels of miR-125b were significantly asso-
ciated with shorter RFS (P = 0.03 by log-rank test)
(Table 4). Conversely, miR-205 or miR-424 expression
levels displayed no prognostic value in the HR+/HER2−
breast cancer subclass (P = 0.5 and P = 0.8, respectively, by
Figure 4 (See legend on next page.)
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Figure 4 MicroRNA-125b and microRNA-205 overexpression and microRNA-424 expression silencing increase aggressiveness in
MCF-7aro cells. (A) Primary mammospheres (PMs) formation assay. MCF-7aro, Res-Let, Res-Ana and MCF-7aro cells transfected by microRNA
(miR)-125b-5p or miR-205-5p mimic, miR-424-3p inhibitor or their negative controls were cultured in nonadherent mammosphere culturing
conditions. (B) Second-generation mammospheres generated from the PMs shown in (A). Data given in (A) and (B) are the mean ± SD of three
independent experiments. (C) Growth kinetics of MCF-7aro, Res-Ana and Res-Let cells in steroid-free medium. (D) Growth kinetics in steroid-free
conditions of MCF-7aro cells transiently transfected with either the negative control of mimics, miR-125b-5p or miR-205-5p or (E) the negative
control of inhibitor or miR-424-3p inhibitor. (C), (D) and (E) show the results representative of at least three independent experiments. *P < 0.05,
**P < 0.01 and ***P < 0.001 (Student’s t-test).
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of miR-125b expression were still significantly associated
with shorter RFS in luminal A breast cancers (P = 0.05)
(Table 4), but they were not informative in luminal B
breast cancers (Table 4). Altogether, these data suggest
that miR-125b expression would add significant prognos-
tic value to the luminal A subtype, where miR-125b ex-
pression would differentiate between excellent and
intermediate or poor luminal A relapse-free survivors.
We aimed to investigate the association between the
miR-125b marker and the clinical response of the
HR+ breast cancer patients treated with endocrine
therapy alone or in combination with chemotherapy.
In the HR+/HER2− and luminal A subclasses, all pa-
tients except one were treated with endocrine therapy
alone or in combination with chemotherapy; removing
this patient from the HR+/HER2− or the luminal
A subclass had no impact on the statistical signifi-
cance of the results in univariate analysis (P = 0.03 and
P = 0.05, respectively) (data not shown). We usedTable 2 The top-ranked signaling pathways associated with r
Dereg
Res-Le
KEGG pathway Pathway ID P-valu
Wnt signaling pathway hsa04310 7.1 × 1
TGF-β signaling pathway hsa04350 2.1 × 1
Axon guidance hsa04360 2.9 × 1
Regulation of actin cytoskeleton hsa04810 1.0 × 1
MAPK signaling pathway hsa04010 1.3 × 1
Focal adhesion hsa04510 3.0 × 1
Adherens junction hsa04520 2.0 × 1
Insulin signaling pathway hsa04910 1.6 × 1
Ubiquitin-mediated proteolysis hsa04120 1.1 × 1
ErbB signaling pathway hsa04012 1.3 × 1
Tight junction hsa04530 7.1 × 1
Phosphatidylinositol signaling system hsa04070 1.3 × 1
mTOR signaling pathway hsa04150 3.0 × 1
aMAPK, Mitogen-activated protein kinase; mTOR, Mammalian target of rapamycin; N
growth factor β. bP-value was obtained using the DIANA-mirPath algorithm to ident
signaling pathways predicted to be altered by the microRNAs selected in our studyFisher’s exact test to investigate the association
between the miR-125b marker and the clinical
response of all the HR+ breast cancer patients treated
with endocrine therapy alone or in combination with
chemotherapy, whose clinical response was fully
known at the 7-year follow-up examination. Whereas
miR-205 and miR-424 expression levels showed
no significant association, high miR-125b expression
levels were associated with earlier relapse in this HR+
subgroup (P = 0.02) (Additional file 7: Table S3). Only
four patients were treated with endocrine therapy
alone, one of whom (treated with letrozole) displayed
high miR-125b expression levels in the tumor sample
and relapsed (and died at 1.7 years). The other three
patients had not relapsed at the 7-year follow-up
examination. Altogether, these data suggest that miR-
125b expression levels are a novel biomarker of poor
prognosis in breast cancer and are associated with
earlier relapse in HR+ breast cancer treated with








0−9 7.0 × 10−7
0−8 3.0 × 10−4
0−8 7.2 × 10−8
0−7 1.5 × 10−5
0−7 1.8 × 10−4 Yes
0−7 8.2 × 10−10 Yes
0−6 2.4 × 10−6
0−5 3.5 × 10−10 Yes
0−4 4.5 × 10−5
0−4 4.5 × 10−6 Yes
0−4 NP Yes
0−3 NP Yes
0−3 2.8 × 10−5 Yes
P, Not present in the top-ranked signaling pathways; TGF-β, Transforming
ify significantly deregulated Kyoto Encyclopedia of Genes and Genomes (KEGG)
(Table 1).
Figure 5 (See legend on next page.)
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Figure 5 The PI3K/AKT/mTOR pathway is targeted by the microRNAs deregulated in the aromatase inhibitor-resistant cells. (A) Overview of
the AKT signaling pathway illustrating the results of our analysis. Genes in yellow rectangles represent the genes targeted by microRNAs (miRs)
miR-125b, miR-205, miR-424 and miR-30a. (B) Western blot analysis of the AKT pathway in MCF-7aro and Res-Let cells. (C) Western blot analysis of the
AKT pathway in MCF-7aro cells transfected with the mimic of miR-125b-5p or miR-205-5p, the inhibitor of miR-424-3p, or their respective negative
controls. (D) Western blot analysis of the AKT pathway activation status in Res-Let cells transfected with the inhibitor of miR-125b-5p or miR-205-5p,
the mimic of miR-424-3p, or their respective negative controls. (B), (C) and (D) show representative blots from three independent experiments and cell
lysates. The relative expression levels of the corresponding ratio of phosphorylated to total proteins were quantified, and these data are shown below
the blots.
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increases sensitivity to letrozole and overcomes
resistance
Because high expression levels of miR-125b led to AI re-
sistance and activation of the AKT/mTOR pathway in
breast cancer cells and were also associated with poor
prognosis among our cohort, we hypothesized that ac-
quisition of deregulated miR-125b expression represents
an alternative trick used by HR+ AI-resistant breast can-
cer cells to activate this crucial survival pathway. Inter-
estingly, in contrast to the Res-Let and Res-Ana cells,
new cellular models of acquired resistance to 4-hydroxy-
tamoxifen (OH-Tam) (Res-Tam cells) or to fulvestrant
(Res-Fulv cells), established by long-term exposure of
MCF-7aro to the corresponding drugs (Additional file 8:
Figures S4A and S4B), displayed no clear constitutive ac-
tivation of the AKT/mTOR pathway (Additional file 8:
Figure S4C). This suggests that these specific Res-Tam
and Res-Fulv cells have developed alternative me-
chanisms of endocrine resistance. Interestingly, neither
of these two cell lines displayed any deregulated miR-
125b expression levels (Additional file 8: Figure S4D).Table 3 Univariate and multivariate analyses of the prognost





miR-125b-5p expression levels 65 6.80 (
miR-205-5p expression levels 65 1.86 (
miR-424-3p expression levels 65 1.04 (
Age (≤50 yr; >50 yr) 65 0.02 (
Macroscopic tumor size (≤30 mm; >30 mm) 64c 1.47 (
Lymph node status (≤3; >3) 65 7.68 (
Histological grade (SBR1 + SBR2; SBR3) 65 0.45 (
Histological grade (SBR1; SBR2) 22 1.41 (
Histological grade (SBR1; SBR3) 47 0.48 (
Histological grade (SBR2; SBR3) 61 1.10 (
ER status (negative; positive) 65 0.17 (
PR status (negative; positive) 65 0.10 (
HER2 status (negative; positive) 65 0.78 (
a95% CI, 95% confidence interval; ER, Estrogen receptor; HER2, Human epidermal g
NS, Not significant; PR, Progesterone receptor; SBR, Scarff-Bloom-Richardson grade.Altogether, these data suggest that increased miR-125b
expression levels in the Res-Let and Res-Ana cells, as
compared with control cells, constitute an important
mechanism developed by these two AI-resistant cells
that leads to activation of the AKT/mTOR pathway.
We then wished to determine whether miR-125b and
AKT activation paired with miR-125b overexpression
would constitute relevant targets to overcome letrozole
resistance. Strikingly, silencing miR-125b in Res-Let
cells, paired with a decreased activation of the AKT/
mTOR pathway (Figure 5D), led to a significant increase
in sensitivity to letrozole (Figure 6C). We also investi-
gated the impact of a pan-AKT inhibitor, MK-2206, on
the letrozole response of MCF-7aro cells transfected by
the mimic of miR-125b. MK-2206 is a highly selective
non-ATP–competitive, allosteric AKT inhibitor that in-
hibits the activities of the three human AKT isoforms.
Our group has previously verified that exposure to MK-
2206 induces inhibition of the AKT pathway (significant
decrease in the phosphorylation status of AKT, together
with a significant decrease in the phosphorylation levels
of GSK-3β and p70S6K [6]). Strikingly, in the MCF-7aroic value of miR-125b-5p, miR-205-5p and miR-424-3p
e-free survivala
riate Multivariate
5% CI) P-valueb HR (95% CI) P-valueb
1.35 to 35.26) 0.009 6.35 (1.21 to 33.27) 0.029
0.63 to 10.40) NS (0.17) ND ND
0.52 to 7.58) NS (0.31) ND ND
0.54 to 2.03) NS (0.90) ND ND
0.08 to 1.89) NS (0.22) ND ND
1.42 to 33.15) 0.006 6.29 (1.27 to 31.07) 0.024
0.35 to 8.18) NS (0.50) ND ND
0.01 to 3.49) NS (0.23) ND ND
0.06 to 4.00) NS (0.49) ND ND
0.36 to 23.68) NS (0.29) ND ND
0.20 to 2.85) NS (0.68) ND ND
0.21 to 3.04) NS (0.75) ND ND
0.48 to 6.84) NS (0.38) ND ND
rowth factor receptor 2; HR, Hazard ratio; miR, MicroRNA; ND, Not done;
bP < 0.05 was considered significant. cInformation available for 64 patients.
Figure 6 MicroRNA-125b is a poor prognostic biomarker and represents a therapeutic target to overcome letrozole resistance.
(A) Kaplan-Meier analysis (log-rank test) for relapse-free survival (RFS) is shown in a cohort of primary breast tumor samples (n = 65). (B) Effect of
the microRNA (miR) miR-125b-5p expression level and lymph node status signature on RFS among our cohort with 65 breast tumors. (C) Cell
viability in response to letrozole in Res-Let cells transiently transfected with either miR-125b-5p inhibitor or its negative control. (D) Cell viability in
response to letrozole (10−5 M) and/or MK-2206 (10−9 M) in MCF-7aro cells transiently transfected with either miR-125b-5p mimic or its negative
control. (C) and (D) are representative of at least three independent experiments. ***P < 0.001 (Student’s t-test).
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the pan-AKT inhibitor MK-2206 with letrozole signifi-
cantly restored sensitivity to letrozole, as shown by the
significant decrease in cell viability compared with MK-
2206 or letrozole alone (P < 0.001) (Figure 6D). More
interestingly, the restored sensitivity to letrozole became
similar to the letrozole sensitivity observed in MCF-7aro
cells transfected by the negative control mimic (Figure 6D).
Altogether, these data suggest that, in addition to its likely
being a marker of poor prognosis in breast cancer cells,
miR-125b may also represent a candidate therapeutic
target to counteract letrozole resistance.Discussion
Although AI endocrine therapy provides obvious clinical
benefits, the molecular mechanisms involved in resis-
tance to AIs remain poorly described. To gain further
insight into the molecular mechanisms underlying the
AI resistance, recent whole-genome analyses using AI
pretreatment tumor biopsies accrued from patients in
AI neoadjuvant studies to delineate the mutational land-
scape associated with AI response strategies are of great
interest [48]. However, for preclinical studies, few cellu-
lar models mimicking resistance to AIs are currently
available. Because breast cancer cell lines usually display
Table 4 Univariate analysis of the prognostic value of miR-125b-5p expression levels in relation to relapse-free survival




Hazard ratio 95% CI P-valueb
All breast tumor samples 65 6.80 1.35 to 35.26 0.009
HR+/HER2− subclass 30 4.81 N/A 0.03
Luminal A subclass (HR+, HER2−, SBR1 or SBR2)c 19 3.75 N/A 0.05
Luminal B subclass (HR+, HER2+ and/or SBR3)c 17 1.69 0.07 to 17.12 0.96
a95% CI, 95% confidence interval; HER2, Human epidermal growth factor receptor 2; HR+, Hormone receptor–positive (estrogen receptor (ER) and/or progesterone
receptor (PR)); miR, MicroRNA; N/A, Not applicable as there is no relapse event in the low miR-125b-5p expression level group; SBR, Scarff-Bloom-Richardson grade.
bP < 0.05 was considered significant. cSubclasses of breast cancer were determined using immunohistological (ER, PR, HER2) and SBR grades according to the
St Gallen recommendation [38].
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the most relevant cells in which to study the response to
AIs are cells transfected with the human aromatase gene.
Among the cellular models proposed to study AI re-
sistance, aromatase-transfected and long-term estrogen-
deprived (LTED) cell lines have been proposed, based on
the hypothesis that lack of hormone in the environment
could mimic the withdrawal of estrogen that occurs
during treatment with AIs [39,49]. Most preclinical studies
investigating AI resistance have been conducted on LTED
models, but it has previously been shown that LTED cells
are not totally equivalent to models of endocrine therapy-
acquired resistance [26,39,49,50]. Indeed, genome-wide
analysis revealed important gene expression profile differ-
ences between the AI-resistant and LTED cell lines and
also among the AI-resistant cell lines themselves [39].
Supporting data came from the observation that activated
signaling pathways observed in LTED cells were different
from those observed in long-term AI-treated cells [49,50].
More importantly, the only study in which miRNA ex-
pression profiles associated with AI resistance were inves-
tigated clearly demonstrated that specific miRNA profiles
could be inversely regulated between AI-resistant cells
and LTED cells [26]. In particular, miR-128a, which was
found to regulate TGF-β signaling in letrozole-resistant
breast cancer cells, was upregulated in letrozole-resistant
cells, but not in LTED cells [26]. Thus, cellular models
established according to a protocol that mimics clinical
treatment [2,6,39,50,51] (that is, long-term exposure to
AIs) may more closely reflect the clinical situation and
may be pertinent to investigation of acquired AI resis-
tance. Few of such in vitro models are currently avail-
able [2,5,6,39,41].
Deciphering miRNA deregulations as new mechanisms
associated with acquired AI endocrine resistance re-
mains poorly investigated, and to date only one previous
study team, using an “omics miRNA” approach, identi-
fied one particular miRNA associated with letrozole re-
sistance [26]. In the present study, we aimed to capture
a global view of the miRNA expression profiles asso-
ciated with letrozole and anastrozole resistance in thehope of identifying common miRNA-targeted specific
functional networks and relevant miRNAs (candidate
biomarkers or putative therapeutic targets of ER+ breast
cancers treated by AIs). We performed a large-scale
miRNA analysis using two in vitro cellular models of
acquired AI resistance (Res-Let and Res-Ana cells). Im-
portantly, these cells are total populations of AI-resistant
cells and may thus also mimic the heterogeneous pheno-
type and behavior of resistant cells possibly present in
the tumors of patients who relapse under AI endocrine
therapy.
The AKT/mTOR pathway is known to play a pivotal
role in AI resistance [2,5,6,39,41]. Among the molecular
mechanisms leading to activation of the AKT/mTOR
pathway in AI-resistant cells, special attention has pre-
viously been given to the upstream ErbB family recep-
tors [52]. Importantly, in a recent study, researchers
found that in breast cancer cells with acquired letrozole
resistance, the constitutive activation of the AKT/mTOR
pathway could be blocked by PI3K and/or mTOR inhibi-
tors, but not by EGFR/ErbB2 inhibitors [2]. This obser-
vation strongly supports the existence of a mechanism
other than activation of receptors upstream of the AKT
pathway. Our data show, for the first time to our know-
ledge, that acquisition of deregulated miRNA expression
represents an alternative trick used by ER+ AI-resistant
breast cancer cells to activate this crucial survival path-
way and thus escape from AI endocrine therapy.
A growing body of evidence developed over the last sev-
eral years supports the existence, within a given tumor, of
separate cell subpopulations that have acquired different
mechanisms, all converging to activate the same func-
tional survival network [53]. Consistent with this idea, the
Res-Let or Res-Ana cells develop a deregulated network of
several miRNAs, each independently capable of leading
(or predicted to lead) directly or indirectly to the activa-
tion of the AKT/mTOR pathway. Among the miRNAs
identified in our study, deregulated expression of miR-23b
[54], miR-494 [55], miR-21 [56-58], miR-301 [59] or miR-
193a [60] has previously been shown to induce the activa-
tion of the AKT pathway in different cancer contexts.
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pathway and commonly deregulated in both Res-Let and
Res-Ana cells, we then investigated miR-125b, miR-205 and
miR-424 further. Our study has shown, for the first time to
our knowledge, that ectopic overexpression of either miR-
125b or miR-205, or silencing miR-424 expression, in the
sensitive ER+ MCF-7aro cells was sufficient to trigger acti-
vation of the AKT/mTOR pathway, to develop de novo re-
sistance to both letrozole and anastrozole drugs and to
induce the selection of stem-like and tumor-initiating cells
possessing self-renewing properties.
Several previous studies have demonstrated that any
given miRNA could play a dual role (via oncogenic or
tumor-suppressive activities), depending on the tissue or
the tumor. This is likely due to any given miRNA tar-
geting multiple mRNAs, each of which has a different
function in an individual cellular context [11-13,61].
Consistently, miR-424 is known to play a suppressive
role in some tumors [62], whereas high expression levels
have been ascribed to chemotherapy resistance [63,64].
In accordance with our results, decreased levels of miR-
424 led to an activated AKT/mTOR pathway in prostate
and colon cancer cells [65]. MiR-205 also plays a dual
role in carcinogenesis [13]. In its “devil” role (associated
with tumorigenesis), and in accordance with our study,
overexpression of miR-205 has been shown to lead to a
coordinated activation of the AKT signaling pathway in
several cancer contexts [66-69]; to our knowledge,
though, it has never been shown in breast cancer cells.
Complexity is further revealed by the observation that,
conversely, miR-205 is able to inhibit activation of the
AKT pathway [70]. However, it is noteworthy that this
latter study was conducted in ERα-negative breast can-
cer cells, and one can suggest that the ER status of
breast cancer cells provides a cellular context whereby
miR-205 exerts opposite roles.
MiR-125b interferes with many different cellular pro-
cesses and, according to the cellular context, acts as a
tumor suppressor (for example, gliomas, ovarian cancer,
and hepatocellular carcinoma), as an oncogene (for
example, non-small cell lung carcinoma, colon cancer)
or as both (brain tumors or prostate cancer) [12,61]. In
its tumor-suppressive functions, miR-125b has been re-
ported to target ENPEP, CK2-α, CCNJ, MEGF9 [71] or
the proto-oncogene ETS1 [72]. Conversely, in its “devil”
role, high miR-125b expression levels confer to breast
cancer cells resistance to paclitaxel by targeting BAK1
[73] and are detected in miRNA signatures present in
Tam- or fulvestrant-resistant breast cancer cell lines
[17,18]. In a neoadjuvant chemotherapy study in breast
cancer, high expression levels of circulating miR-125b
were detected in nonresponsive patients [74]. One of the
key findings of our study is that miR-125b overexpres-
sion not only enables activation of the AKT/mTORpathway and AI resistance but also confers an estrogen-
independent phenotype to the sensitive ER+ MCF-7aro
cells. Importantly, miR-125b is known to directly target
the p53 tumor suppressor gene and other genes be-
longing to the p53 network [12,61], and p53 is known to
closely interfere and communicate with the cancer rele-
vant PI3K/AKT/mTOR pathway [75-78]. Indeed, p53 is
able to regulate cell survival by inhibiting the PI3K/
AKT/mTOR survival pathway, such as by positively
regulating the expression of AKT/mTOR pathway inhi-
bitors [76,78] or by negative regulating the expression of
PI3KCA, encoding the p110α catalytic subunit of PI3K
[75,77]. Thus, inactivation of p53 and subsequent upregu-
lation of PI3KCA is one of the mechanisms contributing
to the pathophysiology of cancer [75,77]. Interestingly,
transfecting MCF-7aro cells with the mimic of miR-125b
was sufficient to lead to decreased p53 expression levels
(at both the mRNA and protein levels) and to subsequent
increased p110α expression levels (Additional file 9:
Figure S5). These data strongly support that p53-driven
mechanisms could be involved in the activation of the
AKT pathway in the presence of miR-125b. This could
thus represent one possible miR-125b-driven mecha-
nism developed by the AI-resistant cells.
Our work also highlights, for the first time to our know-
ledge, the clinical relevance of miR-125b in breast cancer
by demonstrating that high expression levels of this
miRNA may represent a marker of poor prognosis. Indeed,
assessing miR-125b expression levels (alone or associated
with lymph node status) may allow the restratification of
patients with breast cancer into outcome-dependent sub-
classes. Most importantly, high miR-125b expression levels
were also associated with earlier relapse in ER+ breast can-
cer treated with endocrine therapy. The measurement of
miRNA expression holds great promise, as miRNA can
now be extracted not only from frozen tumor samples but
also from formalin-fixed, paraffin-embedded samples as
well as from serum [11]. Expression levels of miR-125b
could thus represent a new prognostic marker and candi-
date predictor of AI response in breast cancer. We aimed
to investigate the prognostic value of miR-125b using the
miRNA-seq data of The Cancer Genome Atlas (TCGA)
breast cancer cohort [79]. However, the insufficient clinical
follow-up (low number of relapse events and short median
overall follow-up) actually available in this breast cancer
cohort does not allow us to make any statements about the
prognostic value of miR-125b (data not shown). When a
longer median follow-up for the patients in the TCGA co-
hort who have not yet relapsed is available to the scientific
community, it would be of great interest to assess whether
high miR-125b expression levels are also found to be asso-
ciated with shorter RFS in this cohort.
Importantly, reducing miR-125b expression levels in
the letrozole-resistant cells was sufficient not only to
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way but also to overcome letrozole resistance, by resensi-
tizing the resistant cells to AI treatment. In the future,
therapeutic strategies aimed at blocking expression of
miR-125b in endocrine-sensitive primary breast cancer
may reinstate a greater response to AI endocrine therapy
in a subset of breast cancers and/or may prevent the
emergence of miR-125b-overexpressing breast cancer cell
subpopulations evolving toward AI-resistant cells.
Conclusions
Overall, our new findings have important medical implica-
tions. (1) The acquisition of specific deregulated miRNAs
is a newly discovered alternative mechanism developed by
AI-resistant breast cancer cells to achieve constitutive ac-
tivation of the AKT/mTOR pathway and to develop de
novo or acquired resistance to AI. (2) MiR-125b, miR-205
and miR-424 represent important players and are similarly
deregulated in two independent models of AI resistance.
(3) Deregulated expression of these three miRNAs is suffi-
cient to confer AI resistance, activation of the AKT/
mTOR pathway and emergence of a subpopulation of cells
with stem-like properties. (4) MiR-125b expression levels
are informative in breast cancer and may represent a novel
biomarker of poor prognosis associated with relapse in ER
+ breast cancer patients treated with endocrine therapy,
which may ultimately be useful to clinicians in their thera-
peutic decision-making. (5) Clinical strategies designed to
counteract miR-125b-mediated effects could be a valuable
future approach to the management of ER+ breast cancers
that develop resistance to AI endocrine therapy.
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